In the last trading session, 1.94 million BridgeBio Pharma Inc (NASDAQ:BBIO) shares changed hands as the company’s beta touched 1.11. With the company’s per share price at $32.19 changed hands at -$0.82 or -2.48% during last session, the market valuation stood at $6.12B. BBIO’s last price was a discount, traded about -22.62% off its 52-week high of $39.47. The share price had its 52-week low at $21.62, which suggests the last value was 32.84% up since then. When we look at BridgeBio Pharma Inc’s average trading volume, we note the 10-day average is 2.98 million shares, with the 3-month average coming to 2.95 million.
Analysts gave the BridgeBio Pharma Inc (BBIO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.39. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BBIO as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight. BridgeBio Pharma Inc’s EPS for the current quarter is expected to be -0.86.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
Instantly BBIO was in red as seen at the end of in last trading. With action -0.46%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 17.31%, with the 5-day performance at -0.46% in the red. However, in the 30-day time frame, BridgeBio Pharma Inc (NASDAQ:BBIO) is -7.77% down. Looking at the short shares, we see there were 22.16 million shares sold at short interest cover period of 6.64 days.
The consensus price target for the stock as assigned by Wall Street analysts is 45.5, meaning bulls need an upside of 29.25% from its current market value. According to analyst projections, BBIO’s forecast low is 45 with 46 as the target high. To hit the forecast high, the stock’s price needs a -42.9% plunge from its current level, while the stock would need to soar -39.79% for it to hit the projected low.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
Year-over-year growth is forecast to reach -3.65% down from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 46.38M. 13 analysts are of the opinion that BridgeBio Pharma Inc’s revenue for the current quarter will be 45.23M. The company’s revenue for the corresponding quarters a year ago was 211.12M and 2.17M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -78.03%. The estimates for the next quarter sales put growth at 1,986.32%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -3.04%. The 2025 estimates are for BridgeBio Pharma Inc earnings to decrease by -31.31%, but the outlook for the next 5-year period is at 41.46% per year.
BBIO Dividends
BridgeBio Pharma Inc is expected to release its next quarterly earnings report on 2025-Feb-19.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.41% of BridgeBio Pharma Inc shares while 91.10% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 96.32%. There are 91.10% institutions holding the BridgeBio Pharma Inc stock share, with KOHLBERG KRAVIS ROBERTS & CO. L.P. the top institutional holder. As of 2024-06-30, the company held 16.5582% of the shares, roughly 31.06 million BBIO shares worth $786.77 million.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 13.3917% or 25.12 million shares worth $636.31 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund . With 4.82 shares estimated at $155.3 million under it, the former controlled 2.54% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.02% of the shares, roughly 3.85 shares worth around $123.96 million.
